RESULTS OF THE FIRST ROUND OF THE PILOT PROJECT ON SCREENING FOR CERVICAL CANCER IN THE REPUBLIC OF KARAKALPAKSTAN

Cervical cancer ranks 2nd in terms of morbidity and mortality among women, both globally and regionally. To date, there are real technologies for the prevention of cervical cancer, namely, vaccination, screening, and treatment of precancerous conditions of the cervix. The most effective screening for cervical cancer is testing women 30-49 years old for oncogenic types of human papillomavirus (HPV). We conducted HPV testing of 49,002 women of the RK aged 30-55 years, of which 3,307 women (6.8%) were HPV-positive against 45,695 women (93.2%) with a negative test result. Typing showed the occurrence of P1 (type 16) in 33.6% of cases among all HPV+, P3 (31, 33, 35, 52 types) in 24.2%, P5 (39, 56, 66 types) in 18.6%, P4 (51, 59 types) in 11.6%, P2 (18,45 types) in 7.6%, a combination of viruses in 9.4%. The most common type in RK is HPV 16. All HPV-positive women underwent extended colposcopy and treatment of identified precancerous conditions. It should be noted that all HPV+ and treated women did not have any complaints and clinical signs of cervical cancer. Thus, the results of testing for HPV are representative for the Republic of Uzbekistan. HPV testing is an effective screening method for early detection of precancerous conditions and cervical cancer